If you plan to breastfeed, discuss the safety of specific GLP-1 medications with your obstetrician and pediatrician, as limited data exist on these drugs in breast milk
Stacking GLP-1 agonists amplifies side effects without proportional benefit
Similarly, a population-based study in Sweden found that individuals taking GLP-1 agonists for metabolic conditions had a lower incidence of alcohol-related disorders compared to matched controls
While many patients use these medicines without serious issues, individuals have reported serious side effects and are now seeking answers about whether those injuries may be connected to these drugs, and what legal options may be available
The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue Liraglutide in the APP/PS1 mouse model of Alzheimers disease
With these results, Eli Lilly has the primary efficacy data needed to file the NDA, targeted for Q4 2026